Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02368951
Title Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bayer
Indications

Advanced Solid Tumor

Therapies

Aprutumab ixadotin

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST